Bellevue Group AG boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,485,627 shares of the biopharmaceutical company's stock after purchasing an additional 14,342 shares during the quarter. Intra-Cellular Therapies makes up 2.9% of Bellevue Group AG's portfolio, making the stock its 11th biggest holding. Bellevue Group AG owned 2.34% of Intra-Cellular Therapies worth $181,873,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Summit Securities Group LLC acquired a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth $56,000. Capital Performance Advisors LLP purchased a new position in Intra-Cellular Therapies during the 3rd quarter valued at about $74,000. CWM LLC raised its position in Intra-Cellular Therapies by 83.9% during the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 626 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Intra-Cellular Therapies by 40.4% in the third quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company's stock valued at $133,000 after purchasing an additional 521 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of Intra-Cellular Therapies by 9.1% in the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock valued at $181,000 after purchasing an additional 207 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company's stock.
Insiders Place Their Bets
In related news, President Michael Halstead sold 22,869 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.60% of the stock is owned by insiders.
Intra-Cellular Therapies Stock Down 1.1 %
Shares of NASDAQ ITCI traded down $0.94 during trading on Friday, hitting $85.65. 275,834 shares of the company traded hands, compared to its average volume of 582,609. The firm has a market capitalization of $9.08 billion, a P/E ratio of -98.45 and a beta of 0.97. The company has a 50-day moving average price of $80.27 and a 200-day moving average price of $75.55. Intra-Cellular Therapies, Inc. has a 1 year low of $58.92 and a 1 year high of $93.45.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to analysts' expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Intra-Cellular Therapies's revenue was up 39.0% on a year-over-year basis. During the same period last year, the firm posted ($0.25) EPS. Research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.
Analysts Set New Price Targets
ITCI has been the subject of several research reports. Morgan Stanley lifted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Royal Bank of Canada boosted their target price on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an "outperform" rating in a research note on Friday, October 4th. The Goldman Sachs Group decreased their price target on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald reissued an "overweight" rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Finally, UBS Group decreased their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $97.23.
Read Our Latest Stock Report on ITCI
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Further Reading
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
